Emicizumab Dosing in Children and Adults with Hemophilia A: Simulating a User-Friendly and Cost-Efficient Regimen.

Laura H BukkemsKathelijn FischerIdske Kremer-HovingaAnouk A M DonnersKarin FijnvandraatRoger E G SchutgensMarjon H CnossenRon A A Mathôt

Published in: Thrombosis and haemostasis (2021)

This alternative maintenance dosing scheme-applicable in patients with hemophilia A receiving emicizumab prophylaxis-reduces financial costs, avoids medication spillage, and is patient-friendly without loss of efficacy.

Keyphrases

low cost
young adults
case report
healthcare
affordable care act
visible light